|
1
|
Biermann JS, Adkins DR, Agulnik M,
Benjamin RS, Brigman B, Butrynski JE, Cheong D, Chow W, Curry WT,
Frassica DA, et al: Bone cancer. J Natl Compr Canc Netw.
11:688–723. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lindsey BA, Markel JE and Kleinerman ES:
Osteosarcoma overview. Rheumatol Ther. 4:25–43. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
He JP, Hao Y, Wang XL, Yang XJ, Shao JF,
Guo FJ and Feng JX: Review of the molecular pathogenesis of
osteosarcoma. Asian Pac J Cancer Prev. 15:5967–5976. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mirabello L, Troisi RJ and Savage SA:
Osteosarcoma incidence and survival rates from 1973 to 2004: Data
from the Surveillance, Epidemiology, and End Results Program.
Cancer. 115:1531–1543. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Liu S, Geng P, Cai X and Wang J:
Comprehensive evaluation of the cytotoxic T-lymphocyte antigen-4
gene polymorphisms in risk of bone sarcoma. Genet Test Mol
Biomarkers. 18:574–579. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Fan Y, Zhang C, Jin S, Gao Z, Cao J, Wang
A, Li D, Wang Q, Sun X and Bai D: Progress of immune checkpoint
therapy in the clinic (Review). Oncol Rep. 41:3–14. 2019.PubMed/NCBI
|
|
7
|
Wang SD, Li HY, Li BH, Xie T, Zhu T, Sun
LL, Ren HY and Ye ZM: The role of CTLA-4 and PD-1 in anti-tumor
immune response and their potential efficacy against osteosarcoma.
Int Immunopharmacol. 38:81–89. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ledford H, Else H and Warren M: Cancer
immunologists scoop medicine Nobel prize. Nature. 562:20–21. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gibney GT, Weiner LM and Atkins MB:
Predictive biomarkers for checkpoint inhibitor-based immunotherapy.
Lancet Oncol. 17:e542–e551. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Markwick LJ, Riva A, Ryan JM, Cooksley H,
Palma E, Tranah TH, Manakkat Vijay GK, Vergis N, Thursz M, Evans A,
et al: Blockade of PD1 and TIM3 restores innate and adaptive
immunity in patients with acute alcoholic hepatitis.
Gastroenterology. 148:590–602.e10. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Das M, Zhu C and Kuchroo VK: Tim-3 and its
role in regulating anti-tumor immunity. Immunol Rev. 276:97–111.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sakuishi K, Ngiow SF, Sullivan JM, Teng
MW, Kuchroo VK, Smyth MJ and Anderson AC:
TIM3+FOXP3+ regulatory T cells are
tissue-specific promoters of T-cell dysfunction in cancer.
Oncoimmunology. 2:e238492013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li Z, Li N, Li F, Zhou Z, Sang J, Chen Y,
Han Q, Lv Y and Liu Z: Immune checkpoint proteins PD-1 and TIM-3
are both highly expressed in liver tissues and correlate with their
gene polymorphisms in patients with HBV-related hepatocellular
carcinoma. Medicine (Baltimore). 95:e57492016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Present D, Bertoni F, Hudson T and
Enneking WF: The correlation between the radiologic staging studies
and histopathologic findings in aggressive stage 3 giant cell tumor
of bone. Cancer. 57:237–244. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fletcher CDM, Bridge JA, Hogendoorn P and
Mertens F: WHO classification of tumours of soft tissue and
boneLyon: IARC Press; pp. 239–394. 2013
|
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sarsilmaz A, Argin M, Sezak M, Altay C and
Erdogan N: Primary osteosarcoma arising from subcutaneous tissue:
5-year follow-up. Clin Imaging. 36:402–405. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mavrogenis AF, Rossi G, Palmerini E,
Errani C, Rimondi E, Ruggieri P, Soucacos PN and Papagelopoulos PJ:
Palliative treatments for advanced osteosarcoma. J BUON.
17:436–445. 2012.PubMed/NCBI
|
|
19
|
Shang Y, Li Z, Li H, Xia H and Lin Z:
TIM-3 expression in human osteosarcoma: Correlation with the
expression of epithelial-mesenchymal transition-specific
biomarkers. Oncol Lett. 6:490–494. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liu H, Zhi L, Duan N and Su P: Abnormal
expression of Tim-3 antigen on peripheral blood T cells is
associated with progressive disease in osteosarcoma patients. FEBS
Open Bio. 6:807–815. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Piao YR, Jin ZH, Yuan KC and Jin XS:
Analysis of Tim-3 as a therapeutic target in prostate cancer.
Tumour Biol. 35:11409–11414. 2014. View Article : Google Scholar : PubMed/NCBI
|
